Nevertheless, the use of MPA in the PPOS regimen tends to inhibit the pituitary in a more profound manner and therefore requires higher doses of gonadotropin (Gn) than the use of GnRH analogues in patients with PCOS (Wang et al., 2016). Here, GNRH1 is linked to polycystic ovary syndrome.